Shorter All-Oral Regimens for Drug-Resistant TB are Cost-Effective in India: ICMR Study
An economic evaluation published in the Indian Journal of Medical Research has demonstrated that shorter, six-month all-oral treatment regimens for multidrug-resistant and rifampicin-resistant tuberculosis (MDR/RR-TB) are cost-effective and offer improved health outcomes compared to the currently used longer regimens in India.
Published on Feb 12, 2026